The Sentinel II is one of the most non-invasive and yet sensitive pieces of passenger screening machinery fully available to date. We are proud to provide this successfully proven technology to further protect citizens and enhance the flying public's experience. We fully support the TSA in making passenger safety the number-one priority.

We realized that if one could put these molecules in a screening platform, (we) might develop a non-invasive, quick and inexpensive over-the-counter breast cancer screening test.

Designed to detect explosives or narcotics, the Sentinel II is the ideal complement to Smiths Detection's systems already installed in airport security checkpoints, as well as other points of critical infrastructure. The Sentinel II, a proven next-generation technology, adds a critical layer in the effort to maintain a clean and safe environment.

This patent is an important addition to our portfolio of non-invasive detection and monitoring intellectual property. The patent provides for a more efficient method of determining tissue characteristics and may be useful for detecting cervical disease and possibly other cancers as well.

This is the first non-invasive way we have of visualizing the small intestines,

Having the ability to screen individuals from head-to-toe without using a secondary system, will maintain our high throughput and ease passenger waiting time in an already time-sensitive environment, such as a busy airport. A one-step system reduces costs as well as space and power requirements.